Impressive results with a bispecific antibody for ALL

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)

BRCA carrier status as a prognostic factor for prostate cancer

Retrospective study of optimal treatment for intermediate-risk testes cancer

Combined chemo-radiation extends survival for anaplastic oligodendroglial tumours

Effects of age on treatment and outcomes in women with stage IB-IIB cervical cancer

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy

MEK inhibitor, trametinib, improves progression free survival in melanoma

SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma

Drug development in small cell and non-small cell lung cancer

ASCO 2012 Drug Development Research Professorship

Early phase trial of ibrutinib for chronic lymphocytic leukaemia